Venable Partner Paul Strain
was quoted in a November 19 New York Times
article discussing a Manhattan civil court verdict in favor of his client, Merck. The plaintiff alleged that Merck's osteoporosis drug, Fosamax, caused her jawbone to disintegrate. According to the article, this decision represents the second of three bellwether jury trials on this issue to end in Merck's favor.
Commenting on the verdict, Strain said the jury voted seven to zero that Fosamax was not a defective product. "We continue to believe that Fosamax is a good medication for a very bad disease. We think the jury verdict closely supports our belief," he said.